Skip to content

Study · Not a test of the peptide alone · 2026

2 results

Quadruple Non-Insulin Therapy for Advanced Type 2 Diabetes Mellitus With Cognitive Impairment: A Case Report.

Skudar S

Cureus1 May 2026

PMID42226859 (opens in a new tab)PMCIDPMC13222685 (opens in a new tab)DOI10.7759/cureus.108113 (opens in a new tab)PepBankPUB-42226859
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder that often requires treatment intensification over time. In complex patients with multiple comorbidities and cognitive impairment, therapeutic decisions must balance glycemic control with safety and feasibility. We present a 59-year-old male with long-standing T2DM, marked body weight fluctuations, and emerging neurocognitive decline. Baseline glycated hemoglobin (HbA1c) was 9.4%, with progressive improvement to 7.1% under quadruple non-insulin therapy consisting of metformin, sitagliptin, glimepiride, and semaglutide. Insulin therapy was avoided due to cognitive impairment and a high risk of dosing errors. Sustained glycemic control was achieved without severe hypoglycemia. This case highlights the importance of individualized, multidisciplinary management in advanced T2DM and demonstrates that non-insulin strategies may be a viable and safe alternative in selected high-risk patients.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a 59-year-old man with long-standing type 2 diabetes, HbA1c fell from 9.4% to 7.1% under quadruple non-insulin therapy (metformin, sitagliptin, glimepiride and semaglutide).

    In plain wordsIn one man with type 2 diabetes, HbA1c fell from 9.4% to 7.1% on a four-drug regimen with semaglutide; semaglutide's own effect is unknown.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change under quadruple non-insulin therapy
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c
    9.4%
    baseline
    HbA1c
    7.1%
    after quadruple therapy

    Source sentences

    Summary
    Baseline glycated hemoglobin (HbA1c) was 9.4%, with progressive improvement to 7.1% under quadruple non-insulin therapy consisting of metformin, sitagliptin, glimepiride, and semaglutide.
    1 context sentence
    Summary · context
    We present a 59-year-old male with long-standing T2DM, marked body weight fluctuations, and emerging neurocognitive decline.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome

    In the same patient, sustained glycemic control was achieved on the quadruple regimen (metformin, sitagliptin, glimepiride and semaglutide) without severe hypoglycemia.

    In plain wordsIn this man, a four-drug regimen with semaglutide kept blood sugar controlled without severe low blood sugar; semaglutide's own effect is unknown.

    Peptide
    Semaglutide
    Outcome
    No significant changeSevere hypoglycemia under quadruple non-insulin therapy
    Study

    n = 1

    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    Sustained glycemic control was achieved without severe hypoglycemia.
    2 context sentences
    Summary · context
    Baseline glycated hemoglobin (HbA1c) was 9.4%, with progressive improvement to 7.1% under quadruple non-insulin therapy consisting of metformin, sitagliptin, glimepiride, and semaglutide.
    Summary · context
    We present a 59-year-old male with long-standing T2DM, marked body weight fluctuations, and emerging neurocognitive decline.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.